OMIM# of the disease
1.4 OMIM# of the gene 172100.
Mutational spectrum
At least sixteen variants have been reported: ten missense variants, three deletion variants, a duplication variant and two splice variants (www.lovd.nl/PGM3). One patient showed a missense variant and on the other allele a deletion of several genes comprising the whole PGM3 gene. The standard reference sequence indicating reported variants (ENSG00000013375) and a reference for exon numbering (ENST00000513973.5) can be found at http://www. ensembl.org.
Analytical methods
Sanger sequencing of the 12 coding exons and flanking intronic sequences of the PGM3 gene (NCBI reference sequence: NM_015599.3).
Analytical validation
Sanger sequencing identifies variants in >99% of patients. Deep intronic variants, large deletions and duplications would not be detected using this approach.
1.8 Estimated frequency of the disease (Incidence at birth ("birth prevalence") or population prevalence. If known to be variable between ethnic groups, please report):
At least thirty-eight genetically confirmed patients (from 16 families) have been reported [1] [2] [3] [4] [5] [6] [7] [8] [9] . The frequency and the prevalence of the disease are not known. O-glycosylation, first reported in 2014 [1] [2] [3] [4] . PGM3, a cytosolic enzyme, catalyzes the reversible conversionof N-acetylglucosamine-6-phosphate into N-acetylglucosamine-1-phosphate, required for the synthesis of UDP-GlcNAc. This hexosamine is used to assemble Nglycans, O-glycans, proteoglycans, and glycolipids. PGM3-CDG is one of the some 130 known congenital disorders of glycosylation (CDG), genetic defects in protein and lipid glycosylation and in the synthesis of glycosylphosphatidylinositol (GPI) anchors. Most CDG are multisystem disorders with prominent neurological involvement. They show a great clinical heterogeneity. PGM3-CDG is a multisystem disorder with predominant immunological involvement. The majority of the patients showed recurrent infections (skin, ears, lungs, gastrointestinal system; mainly S. aureus infections, candidiasis and viral infections), atopic disease (eczema, asthma, multiple allergies), psychomotor disability, failure to thrive, skeletal abnormalities (skeletal dysplasia, scoliosis, brachydactyly), eosinophilia, serum hyper-IgE and decreased CD4 T-cells. Symptoms/signs present in a minority of patients were mainly: facial dysmorphism, short stature, auto-immunity, splenomegaly, neurological problems (hypotonia, ataxia, dysarthria), lung abnormalities (respiratory insufficiency, bronchiectasis), gastrointestinal problems (reflux disease, obstruction, malrotation), renal problems (horseshoe kidney, hydronephrosis), other haematological abnormalities (bone marrow failure, anemia, thrombocytopenia, variable changes in leukocytes), and variable changes in serum IgA, IgG and IgM. Survival ranged from 5 days to over 60 years. Patients have been reported from Africa, Central and North America, Asia and Europe. Current screening tests for defects in N-and O-glycosylation (mainly serum transferrin and apo C-III isoelectrofocusing) show normal results. The diagnosis of PGM3-CDG is based on the clinical acumen of the physician and confirmed by mutation analysis of PGM3. Identification of the pathogenic variant(s) will permit heterozygote detection in the family, and prenatal diagnosis. 
Diagnostic setting

TEST CHARACTERISTICS
CLINICAL UTILITY
(Differential) diagnostics: The tested person is clinically affected
(To be answered if in 1.9 'A' was marked). Symptomatic treatment consists of antibiotic administration and immunoglobulin substitution.
One patient received at 4 months a hematopoietic stem cell transplant with cord blood. After 6 months, leucocytosis had normalized and there were no more infections. Another patient received at 6 months of age a bone marrow transplantation. This was followed by resolution of his neutropenia and lymphocyte function [3] . No long-term follow-up is available.
Prognosis (please describe)
Molecular testing is essential for confirmation of the diagnosis and genetic counselling of the families concerned.
Management (please describe)
PGM3-CDG is a multi-system disease, mainly involving the immune system, the skeleton and the brain. Follow-up by a multidisciplinary team is mandatory. 
Prenatal diagnosis
(To be answered if in 1.9 'D' was marked).
Does a positive genetic test result in the index patient enable a prenatal diagnosis?
Yes. Prenatal diagnosis should be performed by molecular analysis.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Knowledge of the diagnosis will stop unnecessary further investigations, will help patients and parents of affected children in the process of accepting the disease and will make possible to consider treatment options.
